Lexaria Bioscience announces that the U.S. Food and Drug Administration has confirmed effectiveness as of February 28, 2024 of the Company’s investigational new drug application thereby cleared for Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LEXX:
- Lexaria Bioscience prices $3.6M registered direct offering at $2.31 per share
- Lexaria Bioscience submits IND application to FDA for DehydraTECH-CBD trial
- Lexaria Bioscience says ‘never been more confident’ in IP portfolio
- Lexaria Bioscience unveils planned 2024 GLP-1 study program
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream